119 related articles for article (PubMed ID: 18761330)
1. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
3. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Wesierska-Gadek J; Borza A; Komina O; Maurer M
Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
[TBL] [Abstract][Full Text] [Related]
4. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
Wesierska-Gadek J; Wandl S; Kramer MP; Pickem C; Krystof V; Hajek SB
J Cell Biochem; 2008 Dec; 105(5):1161-71. PubMed ID: 18846503
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
[TBL] [Abstract][Full Text] [Related]
6. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
Wesierska-Gadek J; Gueorguieva M; Horky M
Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
[TBL] [Abstract][Full Text] [Related]
7. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
Wesierska-Gadek J; Gueorguieva M; Kramer MP; Ranftler C; Sarg B; Lindner H
J Cell Biochem; 2007 Dec; 102(6):1405-19. PubMed ID: 17975794
[TBL] [Abstract][Full Text] [Related]
8. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
[TBL] [Abstract][Full Text] [Related]
9. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Wesierska-Gadek J; Schmitz ML; Ranftler C
J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
[TBL] [Abstract][Full Text] [Related]
10. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
Komina O; Wesierska-Gadek J
Biochem Pharmacol; 2008 Dec; 76(11):1554-62. PubMed ID: 18761329
[TBL] [Abstract][Full Text] [Related]
11. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
12. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.
Wesierska-Gadek J; Borza A; Walzi E; Krystof V; Maurer M; Komina O; Wandl S
J Cell Biochem; 2009 Apr; 106(5):937-55. PubMed ID: 19180585
[TBL] [Abstract][Full Text] [Related]
13. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
Maurer M; Komina O; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():250-6. PubMed ID: 19723062
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
16. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
17. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
[TBL] [Abstract][Full Text] [Related]
18. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
19. Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine.
Videla-Richardson GA; Furmento VA; Garcia CP; Morris-Hanon O; Sevlever GE; Romorini L; Scassa ME
BMC Mol Cell Biol; 2019 Aug; 20(1):40. PubMed ID: 31462218
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
Wesierska-Gadek J; Maurer M; Schmid G
J Cell Biochem; 2007 Oct; 102(3):736-47. PubMed ID: 17415788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
